No Data
HBM, SKB Biopharma Sign License Agreement for Anti-Asthma, COPD Drug
CMB International: Maintains SKB BIO-B "Buy" rating with a Target Price of 227.88 Hong Kong dollars.
Zhaoyin International released a research report stating that it maintains a "Buy" rating for SKB BIO-B (06990), Bullish on the sales target of SKB264 of 0.8-1 billion yuan in 2025, and expects that this year SKB264 will be approved for second-line/third-line EGFR-TKI resistant non-small cell lung cancer. The company's Target Price has been adjusted to 227.88 HKD. Zhaoyin International's main points are as follows: SKB378 is a TSLP monoclonal antibody co-developed by Korunbo Tai and Huanbo Pharmaceutical, which has now been authorized to Windward. The Trade value could reach up to 0.97 billion USD, including 4,500.
Market Alert | Soared 140% in the last month! Huanbo Pharmaceutical today rises over 13% again, securing approximately a 1 billion USD overseas cooperation license agreement.
In terms of news, HBM HOLDINGS-B announced a licensing agreement with Kelun-Bota regarding HBM9378/SKB378 and Windward Bio AG (hereinafter referred to as 'Windward Bio').
On January 10, HBM HOLDINGS-B (02142.HK) spent 0.374 million Hong Kong dollars to repurchase 0.156 million shares.
On January 10, Gelonghui announced that HBM HOLDINGS-B (02142.HK) spent 0.374 million HKD to repurchase 0.156 million shares.
Express News | Windward Bio Launches With $200 Million Series a Financing to Develop Phase 2-Ready, Long-Acting Anti-Tslp Antibody With Best-in-Class Potential in Asthma and Copd
Express News | Hbm Holdings: $45 Mln Upfront & Near-Term Milestone Payments Include Both Cash Payment & Equity Interest in Windward Bio's Parent Company
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
